243 related articles for article (PubMed ID: 26922228)
1. Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives.
Eldehna WM; Abou-Seri SM; El Kerdawy AM; Ayyad RR; Hamdy AM; Ghabbour HA; Ali MM; Abou El Ella DA
Eur J Med Chem; 2016 May; 113():50-62. PubMed ID: 26922228
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
4. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors.
El-Helby AA; Ayyad RRA; Sakr H; El-Adl K; Ali MM; Khedr F
Arch Pharm (Weinheim); 2017 Dec; 350(12):. PubMed ID: 29131379
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
[TBL] [Abstract][Full Text] [Related]
7. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.
Abou-Seri SM; Eldehna WM; Ali MM; Abou El Ella DA
Eur J Med Chem; 2016 Jan; 107():165-79. PubMed ID: 26590508
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition.
Elmeligie S; Aboul-Magd AM; Lasheen DS; Ibrahim TM; Abdelghany TM; Khojah SM; Abouzid KAM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1347-1367. PubMed ID: 31322015
[TBL] [Abstract][Full Text] [Related]
9. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
[TBL] [Abstract][Full Text] [Related]
10. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
[TBL] [Abstract][Full Text] [Related]
13. Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations.
Khedr F; Ibrahim MK; Eissa IH; Abulkhair HS; El-Adl K
Arch Pharm (Weinheim); 2021 Nov; 354(11):e2100201. PubMed ID: 34411344
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Cytotoxic Evaluation of Certain 7-Chloro-4-(piperazin-1-yl)quinoline Derivatives as VEGFR-II Inhibitors.
Aboul-Enein MN; El-Azzouny AM; Ragab FA; Hamissa MF
Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28304102
[TBL] [Abstract][Full Text] [Related]
16. Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity.
Amin KM; Barsoum FF; Awadallah FM; Mohamed NE
Eur J Med Chem; 2016 Nov; 123():191-201. PubMed ID: 27484508
[TBL] [Abstract][Full Text] [Related]
17. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
[TBL] [Abstract][Full Text] [Related]
19. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
20. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]